natgillin/translations-raw huggingface dataset:
At the time haemoglobin ≥ 10.0 g/dL was first achieved, the mean (SD) weightadjusted dose was 0.48 (0.24) mcg/kg (range: 0.0 to 1.7 mcg/kg) weekly for the once weekly group and 0.76 (0.21) mcg/kg (range: 0.3 to 1.5 mcg/kg) biweekly for the once every two week group. 
V času, ko je bila prvič dosežena koncentracija hemoglobina ≥ 100 g/l, je bil povprečni (standardni odklon) na telesno maso prilagojeni odmerek 0,48 (0,24) µg/kg (razpon: 0,0 do 1,7 µg/kg) na teden v skupini z uporabo vsak teden ter 0,76 (0,21) µg/kg (razpon: 0,3 do 1,5 µg/kg) na dva tedna v skupini z uporabo vsaka dva tedna.
Aranesp is used to treat symptomatic anaemia in adult cancer patients with non-bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy. 
Zdravilo Aranesp uporabljamo za zdravljenje simptomatske anemije pri odraslih bolnikih, ki imajo raka, ki ne izhaja iz kostnega mozga (nemieloičnega raka), in dobivajo kemoterapijo.
A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see sections 4.2 and 4.4). 
Ob višjih kumulativnih odmerkih ESA so opažali nagnjenost k višjim ocenam tveganja za umrljivost zaradi vseh vzrokov ter za kardiovaskularne in cerebrovaskularne dogodke; to ni bilo odvisno od prisotnosti ali odsotnosti sladkorne bolezni ali od dializnega stanja (glejte poglavji 4.2 in 4.4).
In a prospective, randomised double-blind, placebo-controlled study conducted in 344 anaemic patients with lymphoproliferative malignancies receiving chemotherapy there was a significant reduction in transfusion requirements and an improvement in haemoglobin response (p < 0.001). 
V prospektivni, randomizirani, dvojno slepi s placebom kontrolirani študiji pri 344 anemičnih bolnikih z limfoproliferativnimi malignomi, ki so dobivali kemoterapijo, so ugotovili značilno zmanjšanje potreb po transfuziji in boljši odziv hemoglobina (p < 0,001).
In a clinical study in 124 paediatric patients with chronic kidney disease receiving or not receiving dialysis aged 1 to 18, patients that were stable on epoetin alfa were randomised to receive either darbepoetin alfa administered once weekly (subcutaneously or intravenously) using a dose conversion ratio of 238:1 or to continue with epoetin alfa therapy at the current dose, schedule, and route of administration. 
V klinični študiji so 124 pediatričnih bolnikov, starih od 1 do 18 let s kronično boleznijo ledvic in zdravljenih ali nezdravljenih z dializo, ki so bili stabilni na epoetinu alfa, randomizirali na uporabo darbepoetina alfa (subkutano ali intravensko) s konverzijskim razmerjem odmerka 238:1 ali na nadaljnjo zdravljenje z epoetinom alfa v trenutnem odmerku, shemi in poti uporabe.
Erythropoietin is a growth factor that primarily stimulates red blood cell production. 
Eritropoetini so rastni dejavniki, ki spodbujajo predvsem nastajanje rdečih krvnih celic.
Source: includes 8 randomised, double-blind, placebo-controlled studies (980291-schedule 1 and 2, 980297, 990114, 20000161, 20010145, 20030232, and 20070782) a Hypersensitivity events includes all events under the hypersensitivity SMQ. 
Vir: vključenih je 8 randomiziranih, dvojno slepih, s placebom kontroliranih študij (980291 - shemi 1 in 2, 980297, 990114, 20000161, 20010145, 20030232 in 20070782).
The frequency is estimated from clinical trial data as common in cancer patients and was also common in the placebo groups. 
Na podlagi podatkov iz kliničnih preskušanj je pogostnost pri onkoloških bolnikih ocenjena kot pogosta; pogosta je bila tudi v skupinah s placebom.
If you miss a dose of Aranesp, you should contact your doctor to discuss when you should receive the next dose. 
Če ste pozabili odmerek zdravila Aranesp, se pogovorite z zdravnikom, da vam bo povedal, kdaj morate prejeti naslednji odmerek.
Step 3: Inject G Hold the stretch or pinch. 
3. korak: Injiciranje G Kožo držite raztegnjeno ali stisnjeno v gubo.
Your doctor has decided that the Aranesp pre-filled pen is the best way for you, a nurse or a carer to inject Aranesp. 
Zdravnik je uporabo napolnjenega injekcijskega peresnika Aranesp ocenil kot najboljši način, da si zdravilo injicirate sami, da vam ga injicira medicinska sestra ali oseba, ki skrbi za vas.
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dL (6.2 mmol/L) to 12 g/dL (7.5 mmol/L). 
Variabilnosti hemoglobina se je treba prilagoditi z uravnavanjem odmerka, pri čemer je treba upoštevati ciljno območje koncentracije hemoglobina od 100 g/l (6,2 mmol/l) do 120 g/l (7,5 mmol/l).
The initial dose by subcutaneous or intravenous administration is 0.45 mcg/kg body weight, as a single injection once weekly. 
Začetni subkutani ali intravenski odmerek je 0,45 µg/kg telesne mase v eni injekciji enkrat na teden.
Put the used pre-filled pen in the sharps disposal container immediately after use. 
Uporabljen napolnjen injekcijski peresnik nemudoma po uporabi dajte v vsebnik za ostre odpadke.
Median overall survival in the epoetin alfa plus SOC group was 17.8 months compared with 18.0 months in the SOC alone group (HR 1.07, 95% CI: 0.97, 1.18). 
Mediano celokupno preživetje v skupini z epoetinom alfa in standardno oskrbo je bilo 17,8 meseca v primerjavi z 18,0 meseca v skupini s samo standardno oskrbo (razmerje ogroženosti 1,07; 95 % IZ: 0,97; 1,18).
Intercurrent infections, inflammatory or traumatic episodes, occult blood loss, haemolysis, severe aluminium toxicity, underlying haematologic diseases, or bone marrow fibrosis may also compromise the erythropoietic response. 
Eritropoetski odziv lahko poslabšajo tudi sočasne okužbe, vnetja ali poškodbe, prikrito izgubljanje krvi, hemoliza, huda toksičnost aluminija, osnovne hematološke bolezni ali fibroza kostnega mozga.
• plan to get pregnant. 
• nameravate zanositi.
You may change the injection site if you notice the area is red or sore. 
Mesto injiciranja lahko zamenjate, če je predel pordel ali boli.
K Examine the injection site. 
B Preglejte mesto injiciranja.
• shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dL (7.5-8.7 mmol/L). 
• skrajšala celotno preživetje in povečala število smrti, ki jih je bilo mogoče pripisati napredovanju bolezni po 4 mesecih, pri bolnicah z metastatskim rakom dojke, zdravljenih s kemoterapijo, če je bila ciljna vrednost hemoglobina od 120 do 140 g/l (od 7,5 do 8,7 mmol/l).
This has been predominantly reported in patients with CRF treated subcutaneously. 
O tem so poročali predvsem pri bolnikih s kronično odpovedjo ledvic, ki so zdravilo dobivali subkutano.
In a randomised, double-blind, placebo-controlled phase 3 study 2,549 adult patients with anaemia receiving chemotherapy for the treatment of advanced stage non-small cell lung cancer (NSCLC), were randomised 2:1 to darbepoetin alfa or placebo and treated to a maximum Hb of 12 g/dL. 
V randomizirani, dvojno slepi, s placebom kontrolirani študiji faze 3 je sodelovalo 2.549 odraslih bolnikov z anemijo, zdravljenih s kemoterapijo za zdravljenje napredovalega nedrobnoceličnega raka pljuč, ki so jih randomizirali v razmerju 2 : 1 v skupini z darbepoetinom alfa ali placebom in zdravili do največje koncentracije Hb 120 g/l.
In a randomised clinical study 114 paediatric patients aged 2 to 18 with chronic kidney disease receiving or not receiving dialysis who were anaemic (haemoglobin < 10.0 g/dL) and not being treated with an ESA were administered darbepoetin alfa weekly (n = 58) or once every two weeks (n = 56) for the correction of anaemia. 
V randomizirani klinični študiji je 114 pediatričnih bolnikov, starih od 2 do 18 let s kronično boleznijo ledvic in zdravljenih ali nezdravljenih z dializo, ki so bili anemični (hemoglobin < 100 g/l) in niso prejemali ESA, za korekcijo anemije dobivalo darbepoetin alfa vsak teden (n = 58) ali vsaka dva tedna (n = 56).
Pack size of 1 or 4 vials. 
Pakiranje vsebuje 1 ali 4 viale.
Pharmacokinetic parameters did not change on multiple dosing over 12 weeks (dosing every week or every two weeks). 
Med večkratnim odmerjanjem v teku 12 tednov (odmerjanje vsak teden ali na dva tedna) se farmakokinetični parametri niso spremenili.
Following subcutaneous administration of 2.25 mcg/kg to adult cancer patients a mean peak concentration of 10.6 ng/mL (SD 5.9) of darbepoetin alfa was reached at a mean time of 91 hours (SD 19.7). 
Pri odraslih onkoloških bolnikih je darbepoetin alfa po subkutani uporabi 2,25 µg/kg dosegel povprečno največjo koncentracijo 10,6 ng/ml (standardni odklon 5,9) v povprečno 91 urah (standardni odklon 19,7).
Additionally, do not leave the syringe exposed to direct sunlight. 
Pazite tudi, da injekcijska brizga ne bo izpostavljena neposredni sončni svetlobi.
For all adult and paediatric patients ≥ 1 year of age with chronic renal failure, once your anaemia is corrected you will continue to receive Aranesp given as a single injection, either once a week or once every two weeks. 
Vsi odrasli in pediatrični bolniki, stari ≥ 1 leta, s kronično odpovedjo ledvic bodo po korekciji anemije še naprej prejemali zdravilo Aranesp kot eno injekcijo enkrat na teden ali enkrat na dva tedna.
Your doctor, nurse or pharmacist will show you how to inject yourself with the pre-filled syringe. 
Zdravnik, medicinska sestra ali farmacevt vam bodo pokazali, kako si zdravilo injicirate z napolnjeno injekcijsko brizgo.
PRCA means that the body has stopped or reduced the production of red blood cells which causes severe anaemia. 
Čista aplazija rdečih celic pomeni, da so v telesu nehale nastajati rdeče krvne celice ali pa je njihovo nastajanje zmanjšano; posledica je huda anemija.
placebo-controlled studies of Aranesp with a total of 4,630 patients (Aranesp 2,888, placebo 1,742). 
Aranesp 2.888, placebo 1.742).
Leave the pre-filled pen at room temperature for at least 30 minutes before injecting. 
Pustite napolnjen injekcijski peresnik na sobni temperaturi vsaj za 30 minut, preden začnete z injiciranjem.
You may notice a small air bubble in the pre-filled syringe. 
V napolnjeni injekcijski brizgi boste morda opazili majhen mehurček zraka.
Stop using Aranesp if you develop these symptoms and contact your doctor or seek medical attention immediately. 
Če se vam pojavijo ti simptomi, takoj prenehajte uporabljati zdravilo Aranesp in se nemudoma posvetujte s svojim zdravnikom ali nemudoma poiščite zdravniško pomoč.
Aranesp contains sodium 
Zdravilo Aranesp vsebuje natrij
You could have serious problems if you use more Aranesp than you need, such as very high blood pressure. 
Če ste uporabili večji odmerek zdravila Aranesp, kot bi smeli Če uporabite večji odmerek zdravila Aranesp, kot bi smeli, se vam lahko pojavijo resne težave, kot je zelo visok krvni tlak.
• Keep the pre-filled pen in the outer carton in order to protect from light or physical damage. 
• Napolnjen injekcijski peresnik shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo ali poškodbo.
Marketing Authorisation Holder and Manufacturer Amgen Europe B.V. 
Imetnik dovoljenja za promet z zdravilom in proizvajalec Amgen Europe B.V.
Once removed from the refrigerator and has reached room temperature (up to 25ºC) it must either be used within 7 days or disposed of. 
Ko ga vzamete iz hladilnika in doseže sobno temperaturo (do 25 °C), ga morate uporabiti v 7 dneh, sicer ga morate zavreči.
You could have serious problems if you receive more Aranesp than you need, such as very high blood pressure. 
Če ste uporabili večji odmerek zdravila Aranesp, kot bi smeli Če dobite večji odmerek zdravila Aranesp, kot bi smeli, se vam lahko pojavijo resne težave, kot je zelo visok krvni tlak.
The Aranesp (SureClick) pre-filled pen delivers the complete dose of each presentation. 
Zdravilo Aranesp (SureClick) v napolnjenem injekcijskem peresniku zagotavlja celoten odmerek v vsakem pakiranju.
In these patients, erythropoietin deficiency and a reduced response of erythroid progenitor cells to endogenous erythropoietin both contribute significantly towards their anaemia. 
Pri teh bolnikih k anemiji bistveno pripomoreta tako pomanjkanje eritropoetina kot slabši odziv eritroidnih matičnih celic na endogeni eritropoetin.
• a new Aranesp pre-filled syringe; and 
• novo napolnjeno injekcijsko brizgo zdravila Aranesp in • alkoholne zložence ali podobno.
Step 2: Get ready E Pull the grey cap straight off, only when you are ready to inject. 
2. korak: Pripravite se E Ko ste pripravljeni na injiciranje, potegnite sivi pokrovček igle naravnost s peresnika.
Treatment of symptomatic chemotherapy-induced anaemia in cancer patients 
Zdravljenje simptomatske anemije zaradi kemoterapije pri onkoloških bolnikih
Aranesp is supplied ready for use in a vial. 
Zdravilo Aranesp je pripravljeno za uporabo v viali.
In several controlled studies, epoetins have not been shown to improve overall survival or decrease the risk of tumour progression in patients with anaemia associated with cancer. 
V več kontroliranih kliničnih študijah pri bolnikih, ki so imeli anemijo zaradi raka, epoetini niso izboljšali celotnega preživetja in tudi niso zmanjšali tveganja za napredovanje tumorja.
It is important that you do not try to give the injection unless you or your caregiver has received training from your healthcare provider. 
Pomembno je, da si vi ali oseba, ki za vas skrbi, zdravila ne poskušate injicirati sami, dokler vas ali osebo, ki za vas skrbi, tega ne nauči zdravstveni delavec.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. 
Zdravljenje simptomatske anemije pri odraslih onkoloških bolnikih z nemieloičnimi malignomi, ki dobivajo kemoterapijo.
d Dialysis vascular access thrombosis includes all adverse reactions under the dialysis vascular access thrombosis 
d Tromboza dializnega žilnega pristopa vključuje vse neželene učinke, zajete v poizvedbo MedDRA družbe
In patients not on dialysis, Aranesp may continue to be administered as a single injection once weekly or once every two weeks or once monthly. 
Pri bolnikih, ki niso na dializi, se lahko zdravilo Aranesp še naprej uporablja v posamezni injekciji enkrat na teden ali enkrat na dva tedna ali enkrat na mesec.
For patients ≥ 1 year of age, the initial dose by subcutaneous or intravenous administration is 0.45 mcg/kg body weight, as a single injection once weekly. 
Za bolnike, stare ≥ 1 leta, je začetni subkutani ali intravenski odmerek 0,45 µg/kg telesne mase v eni injekciji enkrat na teden.
• Choose a different site each time you give yourself an injection. 
• Vsakič, ko si injicirate zdravilo, izberite drugo mesto.
• non-inferiority of darbepoetin alfa to placebo for overall survival and progression free survival in patients with advanced stage non-small cell lung cancer receiving chemotherapy when administered to a target haemoglobin of 12 g/dL (7.5 mmol/L) (see section 5.1). 
• potrdila, da darbepoetin alfa v primerjavi s placebom nima slabšega vpliva na celokupno preživetje in preživetje brez napredovanja bolezni pri bolnikih z napredovalim nedrobnoceličnim rakom pljuč, zdravljenih s kemoterapijo, če je ciljna vrednost hemoglobina 120 g/l (7,5 mmol/l) (glejte poglavje 5.1).
Step 4: Finish L Dispose of the used pre-filled pen and grey cap. 
4. korak: Zaključek L Uporabljeni napolnjeni injekcijski peresnik in sivi pokrovček igle odvrzite.
The needle cap of the pre-filled syringe or pre-filled pen contains dry natural rubber (a derivative of latex), which may cause allergic reactions. 
Pokrovček igle na napolnjeni injekcijski brizgi ali na napolnjenem injekcijskem peresniku vsebuje suho naravno gumo (derivat lateksa), ki lahko povzroči alergijske reakcije.
If you have questions about how to inject, please ask your doctor, nurse or pharmacist for assistance. 
Če imate vprašanja o injiciranju zdravila, se za pomoč obrnite na zdravnika, medicinsko sestro ali farmacevta.
If you feel unwell in any way you should contact your doctor, nurse or pharmacist immediately. 
Če se počutite kakor koli slabo, se takoj posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
Aranesp (SureClick) is available in packs containing 1 or 4 pre-filled pens. 
Zdravilo Aranesp (SureClick) je na voljo v pakiranjih, ki vsebujejo 1 ali 4 napolnjene injekcijske peresnike.
Aranesp is available in packs of 1 or 4 vials. 
Zdravilo Aranesp je na voljo v pakiranjih po 1 vialo ali 4 vialami.
Convulsions have been reported in patients receiving Aranesp. 
Pri bolnikih, ki so dobivali zdravilo Aranesp, so poročali o konvulzijah.
Cases of severe hypertension have been observed following overdose with Aranesp (see section 4.4). 
Po prevelikem odmerjanju zdravila Aranesp so opažali primere hude hipertenzije (glejte poglavje 4.4).
Serum potassium levels should be monitored regularly during Aranesp therapy. 
Med zdravljenjem z zdravilom Aranesp je treba redno kontrolirati koncentracijo kalija v serumu.
An increased relative risk of thromboembolic events (RR 1.67, 95% CI: 1.35, 2.06; 35 trials and 6,769 patients) was observed in patients treated with recombinant human erythropoietin. 
Pri bolnikih, zdravljenih z rekombinantnim humanim eritropoetinom, so ugotovili večje relativno tveganje za trombembolične dogodke (RT 1,67, 95 % IZ: 1,35, 2,06; 35 preskušanj in 6.769 bolnikov).
Inject the prescribed dose subcutaneously as directed by your doctor, nurse or pharmacist. 
Predpisani odmerek injicirajte pod kožo po navodilu, ki ste ga dobili od zdravnika, medicinske sestre ali farmacevta.
You do not have to remove the air bubble before injecting. 
Tega zračnega mehurčka vam pred injiciranjem ni treba odstraniti.
Your injection is to be given under the skin (subcutaneous), and so you may use the Aranesp pre-filled pen. 
Injekcijo je treba dati pod kožo (subkutano) in tako lahko uporabite zdravilo Aranesp v napolnjenem injekcijskem peresniku.
a Hypersensitivity events includes all events under the hypersensitivity SMQ. 
a Preobčutljivost vključuje vse dogodke, zajete v standardizirano poizvedbo MedDRA glede preobčutljivosti.
The mean haemoglobin at week 28 for r-HuEPO and darbepoetin alfa was 11.1 (SD 1.4) g/dL and 11.1 (SD 1.1) g/dL, respectively. 
Po 28 tednih je bil povprečni hemoglobin v skupini z r-HuEPO 111 (standardni odklon 1,4) g/l in v skupini z darbepoetinom alfa 111 (standardni odklon 1,1) g/l.
Hypersensitivity reactions have been observed in cancer patients in post-marketing experience. 
Pri onkoloških bolnikih so v obdobju trženja zdravila opažali preobčutljivostne reakcije.
Paediatric population with chronic renal failure 
Pediatrična populacija s kronično odpovedjo ledvic
Do not touch this area again before injecting. 
Tega predela se pred injiciranjem ne dotikajte več.
The median time to progression (TTP) based on investigator-determined progressive disease (PD) was 7.5 months in the epoetin alfa plus SOC group and 7.5 months in the SOC group (HR 1.099, 95% CI: 0.998, 1.210). 
Progression), ki temelji na raziskovalčevi oceni napredovanja bolezni, je bil 7,5 meseca v skupini z epoetinom alfa in standardno oskrbo ter 7,5 meseca v skupini s samo standardno oskrbo (razmerje ogroženosti 1,099; 95 % IZ: 0,998; 1,210).
4 single use pre-filled syringes with automatic needle guards. 
4 napolnjene injekcijske brizge za enkratno uporabo z avtomatičnim ščitnikom igle.
If the bone marrow is consistent with PRCA, testing for anti-erythropoietin antibodies should be performed. 
Če se izvid kostnega mozga sklada s čisto aplazijo rdečih celic, je potrebno testiranje za antieritropoetinska protitelesa.
Use a new pre-filled pen. 
Uporabite nov napolnjen injekcijski peresnik.
If an elevated or rising potassium level is observed then consideration should be given to ceasing Aranesp administration until the level has been corrected. 
Če se izkaže, da je kalij zvišan ali se zvišuje, pride v poštev prenehanje uporabe zdravila Aranesp, dokler se koncentracija kalija ne uredi.
Alternatively, in patients not on dialysis, an initial dose of 0.75 mcg/kg may be administered subcutaneously as a single injection once every two weeks. 
Pri bolnikih, ki niso na dializi, je druga možnost začetni odmerek 0,75 µg/kg subkutano v eni injekciji enkrat na dva tedna.
Please tell your doctor if you are suffering or have suffered from: - high blood pressure which is being controlled with medicines prescribed by your doctor; - sickle cell anaemia; - epileptic fits (seizures); - convulsions (fits or seizures); - liver disease; - significant lack of response to medicines used to treat anaemia; or - hepatitis C. 
Zdravniku povejte, če imate ali ste kdaj imeli: - visok krvni tlak, obvladan z zdravili, ki vam jih je predpisal zdravnik; - anemijo srpastih celic; - epileptične napade (napade krčev); - konvulzije (napade ali krče); - bolezen jeter; - izrazito neodzivnost na zdravila za zdravljenje anemije; ali - hepatitis C.
There have been reports of serious hypersensitivity reactions including anaphylactic reaction, angioedema, allergic bronchospasm, skin rash and urticaria associated with darbepoetin alfa. 
V povezavi z darbepoetinom alfa so poročali o resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, angioedemom, alergijskim bronhospazmom, izpuščajem na koži in urtikarijo.
Rotate the injection sites to avoid discomfort at the site of injection. 
Mesto injiciranja krožno menjajte, da se boste izognili neprijetnemu občutku na mestu injiciranja.
Do not twist or bend the grey cap. 
Ne sučite ali upogibajte sivega pokrovčka igle.
c Thromboembolic events adverse reaction includes PT embolism arterial, thrombophlebitis, thrombosis, venous thrombosis limb. 
c Neželeni učinek trombembolični dogodki vključuje naslednje PT: arterijska embolija, tromboflebitis, tromboza,
Dialysis patients converting from once weekly to once every other week dosing with Aranesp should initially receive a dose equivalent to twice the previous once weekly dose. 
Dializni bolniki, ki preidejo z zdravila Aranesp enkrat na teden na zdravilo Aranesp enkrat vsak drugi teden, morajo uvodoma dobiti odmerek, ki ustreza dvojnemu dotedanjemu odmerku enkrat na teden.
What Aranesp contains 
Kaj vsebuje zdravilo Aranesp
1 single use pre-filled syringe with automatic needle guard. 
1 napolnjena injekcijska brizga za enkratno uporabo z avtomatičnim ščitnikom igle.
Syringe safety guard 
Varnostni ščitnik brizge
Find a comfortable, well-lit, clean surface and put all the equipment you need within reach. 
Poiščite primerno, dobro osvetljeno, čisto površino.
Thromboembolic eventsb, including pulmonary embolism 
Žilne bolezni pogosti trombembolični dogodkib, vključno s pljučno embolijo
Please tell your doctor if you are suffering or have suffered from: - high blood pressure which is being controlled with medicines prescribed by your doctor; - sickle cell anaemia; - epileptic fits (seizures); - convulsions (fits or seizures); - liver disease; - significant lack of response to medicines used to treat anaemia; - an allergy to latex (the needle cap on the pre-filled syringe contains a derivative of latex); or - hepatitis C. 
Zdravniku povejte, če imate ali ste kdaj imeli: - visok krvni tlak, obvladan z zdravili, ki vam jih je predpisal zdravnik; - anemijo srpastih celic; - epileptične napade (napade krčev); - konvulzije (napade ali krče); - bolezen jeter; - izrazito neodzivnost na zdravila za zdravljenje anemije; - alergijo na lateks (pokrovček igle na napolnjeni injekcijski brizgi vsebuje snov, pridobljeno iz lateksa); ali - hepatitis C.
There have been reports, from post-marketing experience, of serious hypersensitivity reactions including anaphylactic reaction, angioedema, allergic bronchospasm, skin rash and urticaria associated with darbepoetin alfa. 
V povezavi z darbepoetinom alfa so v obdobju trženja zdravila poročali o resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, angioedemom, alergijskim bronhospazmom, izpuščajem na koži in urtikarijo.